Clinical Trial Update: Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating optimal treatment with bevacizumab in patients with platinum-sensitive recurrent ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: AGO Research GmbH | Conditions: Recurrent Platinum-sensitive Ovarian Cancer | Phase 3 | Status: COMPLETED